GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Moberg Pharma AB (OTCPK:MBGPF) » Definitions » Cyclically Adjusted PS Ratio

MBGPF (Moberg Pharma AB) Cyclically Adjusted PS Ratio : 0.11 (As of May. 15, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Moberg Pharma AB Cyclically Adjusted PS Ratio?

As of today (2025-05-15), Moberg Pharma AB's current share price is $0.8768. Moberg Pharma AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 was $7.70. Moberg Pharma AB's Cyclically Adjusted PS Ratio for today is 0.11.

The historical rank and industry rank for Moberg Pharma AB's Cyclically Adjusted PS Ratio or its related term are showing as below:

MBGPF' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.08   Med: 0.21   Max: 6.03
Current: 0.08

During the past years, Moberg Pharma AB's highest Cyclically Adjusted PS Ratio was 6.03. The lowest was 0.08. And the median was 0.21.

MBGPF's Cyclically Adjusted PS Ratio is ranked better than
97.55% of 734 companies
in the Drug Manufacturers industry
Industry Median: 1.995 vs MBGPF: 0.08

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Moberg Pharma AB's adjusted revenue per share data for the three months ended in Dec. 2024 was $0.002. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $7.70 for the trailing ten years ended in Dec. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Moberg Pharma AB Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Moberg Pharma AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moberg Pharma AB Cyclically Adjusted PS Ratio Chart

Moberg Pharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.11

Moberg Pharma AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.21 0.29 0.11 0.11

Competitive Comparison of Moberg Pharma AB's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moberg Pharma AB's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Moberg Pharma AB's Cyclically Adjusted PS Ratio falls into.


;
;

Moberg Pharma AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Moberg Pharma AB's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.8768/7.70
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moberg Pharma AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 is calculated as:

For example, Moberg Pharma AB's adjusted Revenue per Share data for the three months ended in Dec. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0.002/132.9872*132.9872
=0.002

Current CPI (Dec. 2024) = 132.9872.

Moberg Pharma AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201412 2.580 100.225 3.423
201503 3.352 99.950 4.460
201506 4.403 99.995 5.856
201509 3.160 100.228 4.193
201512 2.432 100.276 3.225
201603 3.294 100.751 4.348
201606 3.419 101.019 4.501
201609 4.829 101.138 6.350
201612 3.710 102.022 4.836
201703 3.789 102.022 4.939
201706 5.089 102.752 6.586
201709 4.408 103.279 5.676
201712 3.500 103.793 4.484
201803 0.000 103.962 0.000
201806 5.260 104.875 6.670
201809 3.939 105.679 4.957
201812 -12.136 105.912 -15.238
201903 0.540 105.886 0.678
201906 0.000 106.742 0.000
201909 1.511 107.214 1.874
202003 0.000 106.563 0.000
202006 0.000 107.498 0.000
202009 0.000 107.635 0.000
202012 0.000 108.296 0.000
202103 0.000 108.360 0.000
202106 0.000 108.928 0.000
202109 0.000 110.338 0.000
202112 0.000 112.486 0.000
202203 0.000 114.825 0.000
202206 0.000 118.384 0.000
202209 0.002 122.296 0.002
202212 0.000 126.365 0.000
202303 0.000 127.042 0.000
202306 0.000 129.407 0.000
202309 0.000 130.224 0.000
202312 0.000 131.912 0.000
202403 0.002 132.205 0.002
202406 0.013 132.716 0.013
202409 0.008 132.304 0.008
202412 0.002 132.987 0.002

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Moberg Pharma AB  (OTCPK:MBGPF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Moberg Pharma AB Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Moberg Pharma AB's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Moberg Pharma AB Business Description

Traded in Other Exchanges
Address
Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Moberg Pharma AB is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of compounds. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.